NCT01247168View on ClinicalTrials.gov

An Open-Label, Dose-Escalation Study of AZD2461

PHASE1CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Refractory Solid TumorsCancer Tumor

Interventions

DRUG

AZD2461

oral capsules, continuous dosing and intermittent dosing

Trial Locations (1)

Unknown

Research Site, Nashville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY